HomepageATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
Vorige slotkoers
$Â 0,22
Jaar-range
$Â 0,11 - $Â 0,89
Gem. volume
27,54K
Koers/winst
-
Dividendrendement
-
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (CAD) | dec 2023info | Wijziging j-o-j |
|---|---|---|
Opbrengst | — | — |
Bedrijfskosten | 4,60Â mln. | -1,42% |
Netto inkomsten | -4,21Â mln. | 2,39% |
Netto winstmarge | — | — |
Winst per aandeel | -0,08 | 0,50% |
EBITDA | — | — |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (CAD) | dec 2023info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 24,91Â mln. | -41,20% |
Totale activa | 56,36Â mln. | -23,56% |
Totale passiva | 30,42Â mln. | -0,13% |
Totaal aandelenvermogen | 25,94 mln. | — |
Uitstaande aandelen | 52,67 mln. | — |
Koers-boekwaardeverhouding | 0,44 | — |
Rendement op activa | -19,71% | — |
Rendement op kapitaal | -41,30% | — |
Kasstroom
Nettomutatie in liquide middelen
| (CAD) | dec 2023info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -4,21Â mln. | 2,39% |
Operationele kasstroom | -3,84Â mln. | -6,66% |
Kasstroom uit beleggingen | 11,04Â mln. | 1.975,38% |
Kasstroom uit financiering | — | — |
Nettomutatie in liquide middelen | 7,20Â mln. | 334,09% |
Vrije kasstroom | -2,47Â mln. | -2.419,13% |
Over
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
Opgericht
2009
Website
Werknemers
11
